Secondary uses of electronic prescribing and pharmacy data in UK hospital care: a national survey.


Journal

BMJ open quality
ISSN: 2399-6641
Titre abrégé: BMJ Open Qual
Pays: England
ID NLM: 101710381

Informations de publication

Date de publication:
17 Jun 2024
Historique:
received: 11 01 2024
accepted: 28 05 2024
medline: 18 6 2024
pubmed: 18 6 2024
entrez: 17 6 2024
Statut: epublish

Résumé

Electronic hospital pharmacy (EHP) systems are ubiquitous in today's hospitals, with many also implementing electronic prescribing (EP) systems; both contain a potential wealth of medication-related data to support quality improvement. The reasons for reuse and users of this data are generally unknown. Our objectives were to survey secondary use of data (SUD) from EHP and EP systems in UK hospitals, to identify users of and factors influencing SUD.A national postal survey was sent out to all hospital chief pharmacists with pre-notifications and follow-up reminders. Descriptive statistical analysis was performed.Of 187 hospital organisations, 65 (35%) responded. All had EHP systems (for ≥20 years) and all reused data; 50 (77%) had EP systems (established 1-10 years) but only 40 (80%) reused data. Reported facilitators for SUD included medication safety, providing feedback, benchmarking, saving time and patient experience. The purposes of SUD included audits, quality improvement, risk management and general medication-related reporting. Earlier introduction of SUD could provide an opportunity to heighten local improvement initiatives.Data from EHP systems is reused for multiple purposes. Evaluating SUD and sharing experiences could provide richer insight into potential SUD and barriers/factors to consider when implementing or upgrading EP/EHP systems.

Identifiants

pubmed: 38886099
pii: bmjoq-2024-002754
doi: 10.1136/bmjoq-2024-002754
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

PLoS One. 2013;8(1):e53369
pubmed: 23335961
Int J Med Inform. 2016 Apr;88:1-7
pubmed: 26878756
Appl Clin Inform. 2021 Oct;12(5):1049-1060
pubmed: 34758493
Mt Sinai J Med. 2011 Nov-Dec;78(6):827-33
pubmed: 22069206
J Am Med Inform Assoc. 2013 May 1;20(3):470-6
pubmed: 23425440
PLoS Med. 2012 Jan;9(1):e1001164
pubmed: 22303286
PLoS One. 2013 Nov 20;8(11):e80378
pubmed: 24278279
Int J Pharm Pract. 2017 Feb;25(1):5-17
pubmed: 27198585
BMJ Qual Saf. 2015 Aug;24(8):505-15
pubmed: 26065466
Yearb Med Inform. 2017 Aug;26(1):68-71
pubmed: 29063536
Cochrane Database Syst Rev. 2007 Apr 18;(2):MR000008
pubmed: 17443629
JAMA. 1998 Oct 21;280(15):1311-6
pubmed: 9794308
J Public Health Med. 1997 Dec;19(4):413-8
pubmed: 9467147
Arch Intern Med. 2003 Jun 23;163(12):1409-16
pubmed: 12824090
BMJ Open. 2019 Dec 5;9(12):e031637
pubmed: 31806611
J Am Med Inform Assoc. 2008 Sep-Oct;15(5):585-600
pubmed: 18579832
Pharmacy (Basel). 2021 Dec 13;9(4):
pubmed: 34941630
Iran Red Crescent Med J. 2013 Oct;15(10):e8436
pubmed: 24693376
J Antimicrob Chemother. 2017 Jul 1;72(7):1880-1885
pubmed: 28369528
J Am Med Inform Assoc. 2002 Sep-Oct;9(5):529-39
pubmed: 12223505
Perspect Health Inf Manag. 2014 Apr 01;11:1g
pubmed: 24808808
BMJ Qual Saf. 2020 Aug;29(8):696-700
pubmed: 32098804
Aust Health Rev. 2019 Jul;43(3):276-283
pubmed: 29754594
Ann Intern Med. 2006 May 16;144(10):742-52
pubmed: 16702590

Auteurs

Navila Talib Chaudhry (NT)

Research Department of Practice and Policy, UCL School of Pharmacy, London, UK n.chaudhry@ucl.ac.uk.

Jonathan Benn (J)

NIHR Yorkshire and Humber Patient Safety Research Collaboration, School of Psychology, University of Leeds, Leeds, UK.

Bryony Dean Franklin (BD)

Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
Centre for Medication Safety and Service Quality, Pharmacy Department, Imperial College Healthcare NHS Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH